Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 11/20 | 0.57 |
| ▸ | SELP | P16109 | 8/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12631208 | 0.92 | SELE (0.53) | SELESELPLGALS3LGALS9LGALS1 | |
| SCHEMBL12310109 | 0.92 | SELE (0.54) | SELESELPLGALS3LGALS9LGALS1 | |
| SCHEMBL12239769 | 0.86 | SELE (0.59) | SELESELPLGALS3LGALS9LGALS1 | |
| SCHEMBL14823281 | 0.86 | SELE (0.55) | SELESELPLGALS3LGALS9LGALS1 | |
| SCHEMBL8515435 | 0.86 | SELE (0.55) | SELESELPLGALS3LGALS9LGALS1 | |
| SCHEMBL8514368 | 0.86 | SELE (0.55) | SELESELPLGALS3LGALS9LGALS1 | |
| SCHEMBL8514365 | 0.86 | SELE (0.55) | SELESELPLGALS3LGALS9LGALS1 | |
| SCHEMBL13077385 | 0.85 | SELE (0.49) | SELELGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL8515429 | 0.84 | SELE (0.56) | SELESELPLGALS3LGALS9LGALS1 | |
| SCHEMBL12240054 | 0.82 | SELP (0.51) | SELESELPLGALS3LGALS9LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279965-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279965-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | SELE 3/4885SELP 12/4885LGALS3 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.